Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258045 | 0.81 | CYP2C19 (0.60) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL29521617 | 0.81 | CYP2C19 (0.60) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL5366124 | 0.81 | ATM (0.43) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL29564949 | 0.80 | ATM (0.65) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL309752 | 0.80 | ATM (0.65) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL29382818 | 0.80 | CYP2C19 (0.69) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL1185308 | 0.80 | CYP2C19 (0.47) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL28585768 | 0.80 | CYP2C19 (0.69) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL3820792 | 0.80 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL5101217 | 0.80 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C19SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025022093-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-01-30 | — | — | WO | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2024222726-A1 | DEGRADATION AGENT FOR CYCLIN-DEPENDENT KINASE (CDK) 12/13, COMPOSITION AND USE THEREOF | 浙江大学 | 2024-10-31 | — | — | WO | disclosed |
| CN-118440054-A | Degradation agent, composition and application of cyclin-dependent kinase 12/13 | 浙江大学 | 2024-08-06 | — | — | CN | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-1569907-A1 | NICOTINAMIDE-BASED KINASE INHIBITORS | Cytopia PTY Ltd (AU) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054977-A1 | NICOTINAMIDE-BASED KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2004-07-01 | — | — | WO | disclosed |
| CN-1430607-A | Benzophenones as inhibitors of IL-1 beta and TNF-alpha | LEO PHARM PROD LTD (DK) | 2003-07-16 | — | — | CN | disclosed |
| EP-1289958-A2 | BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) | Leo Pharma A/S (DK) | 2003-03-12 | — | — | EP | disclosed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | disclosed |
| US-6432962-B2 | Benzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-08-13 | — | — | US | disclosed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| WO-2001090074-A2 | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-11-29 | — | — | WO | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | CYP1A2 19/4885CYP3A4 35/4885CYP2C19 52/4885 |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | IL1B, IL1A, NFKBIA | CYP1A2 380/4885CYP3A4 1015/4885CYP2C19 1139/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | CYP1A2 504/4885CYP3A4 878/4885CYP2C19 880/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CYP1A2 504/4885CYP3A4 878/4885CYP2C19 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.